天坛生物 (600161)
Beijing Tiantan Biological Products Corporation Limited
K-Line Chart
No K-line data available
Company NameBeijing Tiantan Biological Products Co., Ltd.
Listing Date1998-06-16
Issue Price4.07RMB
Registered Capital197737.144610k RMB
Legal RepresentativeYang Huichuan
Registered AddressRoom 521, Building 8, No. 6 Yard, Boxing 2nd Road, Beijing Economic-Technological Development Area, Beijing, China
IndustryBiological Products
Main BusinessResearch, development, and production of blood products using healthy human plasma and specifically immunized human plasma as raw materials, as well as gene recombination technology; conducting blood product business operations.
Company ProfileBeijing Tiantan Biological Products Co., Ltd. (referred to as "Tiantan Bio", stock code: 600161.SH) was listed in 1998. Its main business is the research, development, manufacturing, sales, and consulting services of blood products. After two major asset restructurings in 2010 and 2017, Tiantan Bio became the sole specialized blood products company under China National Biotec Group.
Stock Details
1. Key Indicators
- Total Shares(W): 197737.14
- Circulating A-Shares(W): 197737.14
- Earnings Per Share(RMB): 0.4100
- Net Assets Per Share(RMB): 5.7971
- Operating Revenue(W RMB): 446507.19
- Total Profit(W RMB): 134739.73
- **Net Profit Attributable to Parent(W RMB) **: 81868.63
- Net Profit Growth Rate(%): -22.16
- Weighted Return on Equity(%): 7.1600
- Operating Cash Flow Per Share(RMB): 0.0590
- Undistributed Profit Per Share(RMB): 3.3776
- Capital Reserve Per Share(RMB): 1.2456
2. Main Business
The main business covers:
- Research, development, and production of blood products using healthy human plasma and specifically immunized human plasma as raw materials, as well as employing gene recombination technology.
- Operation of blood product business.
3. Company Basic Information
- Company Name: Beijing Tiantan Biological Products Co., Ltd.
- Listing Date: 1998-06-16
- Industry: Pharmaceutical Manufacturing
- Address: Room 521, Building 8, No. 6 Courtyard, Boxing Second Road, Beijing Economic-Technological Development Area, Beijing
- Website: https://www.tiantanbio.com/
- Company Profile: The company was exclusively established by the Beijing Biological Products Institute in June 1998. The promoter contributed its net assets, converted into 90 million state-owned legal person shares. After the public offering on May 18, 1998, the total share capital at the time of listing reached 120 million shares. The 3 million internal employee shares and the 27 million public shares were listed for trading on the Shanghai Stock Exchange on June 16, 1998, and the internal employee shares became tradable after six months.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | China National Biotec Group Co., Ltd. | General Legal Person | 90250.05 | 45.64 |
| 2 | Chengdu Institute of Biological Products Co., Ltd. | General Legal Person | 6981.74 | 3.53 |
| 3 | Hong Kong Securities Clearing Company Ltd. | Northbound Funds | 5433.12 | 2.75 |
| 4 | Huatai-Pinebridge CSI 300 ETF | Fund | 2027.00 | 1.03 |
| 5 | Beijing Institute of Biological Products Co., Ltd. | General Legal Person | 1880.24 | 0.95 |
| 6 | E Fund CSI 300 Healthcare ETF | Fund | 1486.85 | 0.75 |
| 7 | E Fund CSI 300 Index Fund | Fund | 1460.14 | 0.74 |
| 8 | Emi Kaixin Value Select Hybrid Securities Investment Fund Class A | Fund | 22.00 | 0.01 |
| 9 | Qianhai Kaiyuan Shanghai-Hong Kong-Shenzhen Innovation Growth Flexible Allocation Hybrid Securities Investment Fund Class A | Fund | 16.34 | 0.01 |
| 10 | Emi Xinxuan Quality Hybrid Securities Investment Fund Class A | Fund | 16.00 | 0.01 |
5. Concept Sectors
- Gene Concept
- Hepatitis Concept
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information